Clinical Trial Update: Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 study evaluating postprandial glucose response to empagliflozin in Japanese patients with type 2 diabetes was completed, with results posted in December…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2014-12-24